health pharma news today obesity drugs glp-1 What is the pipeline for future medications for obesity? The GLP-1 Access Gap: Mapping
Description
Many people experience constipation early in treatment
Additionally, these molecules often exist as higher-order aggregates (e.g., multimers), rather than simple monomers, necessitating advanced characterisation
The reimbursement for GLP-1 medication covers a broader patient population, including the patient pool with limited financial resources or inadequate insurance coverage
In this case, Theophyline inhibits Phosphodietrase
Neurochem 128 , 459471 (2014)
The best formulary is one built around trust, not rebates
